ADMA Biologics, Inc.
ADMA
$16.53
-$0.05-0.30%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -25.67% | 207.41% | 500.55% | 5,774.29% | 800.00% |
| Total Depreciation and Amortization | 0.63% | -2.63% | -5.39% | -6.10% | -3.44% |
| Total Amortization of Deferred Charges | -24.61% | -48.32% | -56.77% | -62.36% | -63.34% |
| Total Other Non-Cash Items | 149.31% | -234.97% | -260.66% | -275.17% | -291.68% |
| Change in Net Operating Assets | -652.98% | -260.64% | -859.48% | -129.58% | -83.14% |
| Cash from Operations | -57.53% | -24.50% | 5.07% | 375.08% | 1,248.55% |
| Capital Expenditure | -174.43% | -263.76% | -71.76% | -104.52% | -72.42% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 295.99% | 79.33% | 69.66% | -56.89% | -66.19% |
| Cash from Investing | -155.29% | -236.91% | -61.01% | -102.54% | -72.15% |
| Total Debt Issued | -- | -22.22% | -77.78% | -- | -- |
| Total Debt Repaid | -76.56% | 28.17% | 43.25% | 62.17% | 62.17% |
| Issuance of Common Stock | -60.18% | -57.54% | 316.62% | 207.83% | 578.80% |
| Repurchase of Common Stock | -734.58% | -608.33% | -174.91% | -199.08% | -251.31% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -455.27% | 64.23% | 89.06% | 94.53% | 94.53% |
| Cash from Financing | 24.49% | 0.51% | -57.40% | -60.82% | -49.53% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -129.96% | -301.77% | -92.07% | 210.14% | 247.27% |